PortfoliosLab logoPortfoliosLab logo
RXST vs. IDYA
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

RXST vs. IDYA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in RxSight, Inc. (RXST) and IDEAYA Biosciences, Inc. (IDYA). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

RXST vs. IDYA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
RXST
RxSight, Inc.
-40.88%-69.69%-14.73%218.23%12.62%-29.69%
IDYA
IDEAYA Biosciences, Inc.
-3.62%34.51%-27.77%95.82%-23.14%-3.51%

Fundamentals

Market Cap

RXST:

$253.64M

IDYA:

$2.95B

EPS

RXST:

-$0.95

IDYA:

-$1.28

PS Ratio

RXST:

1.88

IDYA:

13.55

PB Ratio

RXST:

0.92

IDYA:

2.89

Total Revenue (TTM)

RXST:

$134.48M

IDYA:

$218.71M

Gross Profit (TTM)

RXST:

$103.01M

IDYA:

$214.12M

EBITDA (TTM)

RXST:

-$38.63M

IDYA:

-$120.40M

Returns By Period

In the year-to-date period, RXST achieves a -40.88% return, which is significantly lower than IDYA's -3.62% return.


RXST

1D
1.15%
1M
-17.65%
YTD
-40.88%
6M
-31.48%
1Y
-75.60%
3Y*
-28.25%
5Y*
10Y*

IDYA

1D
5.95%
1M
3.48%
YTD
-3.62%
6M
22.45%
1Y
103.42%
3Y*
34.38%
5Y*
6.93%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RXST vs. IDYA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXST
RXST Risk / Return Rank: 77
Overall Rank
RXST Sharpe Ratio Rank: 66
Sharpe Ratio Rank
RXST Sortino Ratio Rank: 66
Sortino Ratio Rank
RXST Omega Ratio Rank: 44
Omega Ratio Rank
RXST Calmar Ratio Rank: 11
Calmar Ratio Rank
RXST Martin Ratio Rank: 1717
Martin Ratio Rank

IDYA
IDYA Risk / Return Rank: 8989
Overall Rank
IDYA Sharpe Ratio Rank: 9090
Sharpe Ratio Rank
IDYA Sortino Ratio Rank: 8686
Sortino Ratio Rank
IDYA Omega Ratio Rank: 8484
Omega Ratio Rank
IDYA Calmar Ratio Rank: 9393
Calmar Ratio Rank
IDYA Martin Ratio Rank: 9292
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RXST vs. IDYA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for RxSight, Inc. (RXST) and IDEAYA Biosciences, Inc. (IDYA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


RXSTIDYADifference

Sharpe ratio

Return per unit of total volatility

-0.91

1.98

-2.89

Sortino ratio

Return per unit of downside risk

-1.47

2.48

-3.94

Omega ratio

Gain probability vs. loss probability

0.78

1.32

-0.54

Calmar ratio

Return relative to maximum drawdown

-1.00

4.76

-5.76

Martin ratio

Return relative to average drawdown

-1.26

12.04

-13.31

RXST vs. IDYA - Sharpe Ratio Comparison

The current RXST Sharpe Ratio is -0.91, which is lower than the IDYA Sharpe Ratio of 1.98. The chart below compares the historical Sharpe Ratios of RXST and IDYA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


RXSTIDYADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.91

1.98

-2.89

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.12

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.27

0.23

-0.50

Correlation

The correlation between RXST and IDYA is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

RXST vs. IDYA - Dividend Comparison

Neither RXST nor IDYA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RXST vs. IDYA - Drawdown Comparison

The maximum RXST drawdown since its inception was -90.53%, which is greater than IDYA's maximum drawdown of -74.64%. Use the drawdown chart below to compare losses from any high point for RXST and IDYA.


Loading graphics...

Drawdown Indicators


RXSTIDYADifference

Max Drawdown

Largest peak-to-trough decline

-90.53%

-74.64%

-15.89%

Max Drawdown (1Y)

Largest decline over 1 year

-76.68%

-20.05%

-56.63%

Max Drawdown (5Y)

Largest decline over 5 years

-69.42%

Current Drawdown

Current decline from peak

-90.42%

-29.30%

-61.12%

Average Drawdown

Average peak-to-trough decline

-34.61%

-30.82%

-3.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

60.76%

7.92%

+52.84%

Volatility

RXST vs. IDYA - Volatility Comparison

The current volatility for RxSight, Inc. (RXST) is 14.41%, while IDEAYA Biosciences, Inc. (IDYA) has a volatility of 15.78%. This indicates that RXST experiences smaller price fluctuations and is considered to be less risky than IDYA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


RXSTIDYADifference

Volatility (1M)

Calculated over the trailing 1-month period

14.41%

15.78%

-1.37%

Volatility (6M)

Calculated over the trailing 6-month period

44.06%

31.74%

+12.32%

Volatility (1Y)

Calculated over the trailing 1-year period

83.74%

52.65%

+31.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

69.18%

59.78%

+9.40%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

69.18%

74.51%

-5.33%

Financials

RXST vs. IDYA - Financials Comparison

This section allows you to compare key financial metrics between RxSight, Inc. and IDEAYA Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
32.61M
10.88M
(RXST) Total Revenue
(IDYA) Total Revenue
Values in USD except per share items